Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent Continue reading QIDP Antibiotics – 2015 Year-End Update
If you were developing a new antibiotic with a novel MoA, one that covers most GPC, most GNR, most anaerobes and atypicals, including many MDR pathogens like MRSA, enterococci (both E. faecalis and E. faecium), and one that has also activity against rickettsiae and bioterrorism agents, you would consider it a Continue reading Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign
The pleuromutilins are a relatively ‘old’ class of antibiotics that have seen much use in veterinary but not in human medicine. According to EMA, Tiamulin is an “essential antibiotic” for the control of dysentery in pigs which is caused by Brachyspira hyodysenteriae, a macrolide-resistant pathogen.[1] Retapamulin / Altabax® was introduced Continue reading BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3